Fisher Asset Management LLC Has $19.86 Million Holdings in Scholar Rock Holding Corporation $SRRK

Fisher Asset Management LLC grew its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 29.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 533,176 shares of the company’s stock after acquiring an additional 120,765 shares during the period. Fisher Asset Management LLC’s holdings in Scholar Rock were worth $19,855,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of SRRK. AQR Capital Management LLC increased its holdings in shares of Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after purchasing an additional 49,217 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Scholar Rock by 12.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after buying an additional 5,831 shares during the last quarter. Millennium Management LLC boosted its position in Scholar Rock by 37.4% in the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after buying an additional 54,555 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Scholar Rock by 25.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after buying an additional 34,594 shares during the period. Finally, Strs Ohio bought a new stake in shares of Scholar Rock during the first quarter worth $77,000. 91.08% of the stock is owned by institutional investors.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $47.43 on Thursday. The stock has a market cap of $4.84 billion, a PE ratio of -13.83 and a beta of 0.70. The stock has a 50-day moving average of $45.32 and a 200-day moving average of $39.14. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter last year, the firm posted ($0.64) EPS. As a group, sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO David Hallal sold 57,450 shares of the company’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $2,453,115.00. Following the completion of the sale, the chief executive officer owned 1,541,645 shares in the company, valued at $65,828,241.50. This represents a 3.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mo Qatanani sold 14,898 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the sale, the insider directly owned 85,660 shares in the company, valued at $4,001,178.60. The trade was a 14.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 208,470 shares of company stock worth $9,201,778 over the last ninety days. Insiders own 13.30% of the company’s stock.

More Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: BMO Capital Markets raised its price target from $50 to $70 and kept an “outperform” rating (~47.6% upside vs. the current price). BMO Raises PT to $70
• Positive Sentiment: Citigroup raised its target to $58 and maintained a “buy” rating (~22% upside). Citigroup Raises PT to $58
• Positive Sentiment: Piper Sandler raised its target to $58 and kept an “overweight” rating (similar ~22% upside). Piper Sandler PT Raise Street Insider
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and a $58 target. HC Wainwright Reaffirmation TickerReport
• Positive Sentiment: Q4 results narrowly beat expectations — reported EPS (net loss) was ($0.76) vs. consensus (~$0.86), which analysts viewed positively relative to estimates. Earnings Release / Summary
• Neutral Sentiment: Full earnings and Q&A transcripts are now available (multiple outlets posted call transcripts), useful for digging into pipeline updates and management tone. Seeking Alpha Transcript InsiderMonkey Transcript
• Negative Sentiment: Despite the beat, the corrected press release clarifies net loss per share was $0.76 for Q4 vs. $0.61 a year earlier — an increase in the loss year‑over‑year, underscoring ongoing unprofitability. BusinessWire Correction

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Truist Financial raised their price target on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $58.00 price target on shares of Scholar Rock in a research report on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Finally, UBS Group began coverage on shares of Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Scholar Rock has an average rating of “Buy” and a consensus target price of $54.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).